The new drug, diagnostic, and vaccine pipeline has never looked more promising for people with HIV, hepatitis C virus (HCV), and tuberculosis (TB), according to a report released today by Treatment Action Group (TAG) and HIV i-Base.
February 7, 2011 Dear Secretary Clinton, We write to ask for your leadership in ensuring The Global Fund to Fight AIDS, TB, and Malaria is “open for new business,” saving lives through expanding programming in 2012. We ask that you…
HIV, Tuberculosis, and Viral Hepatitis: Drugs, diagnostics, Vaccines, Immune-based therapies, and Preventive Technologies in Development. By Polly Clayden, Lei Chou, Simon Collins, Mark Harrington, Richard Jefferys, Eleonora Jimenez, Scott Morgan, Tracy Swan, Javid Syed and Claire Wingfield.
January 2010 - Despite being curable, Tuberculosis (TB) continues to be the leading cause of death among people with HIV in 2008, accounting for 25% of all HIV-related deaths. The World Health Organization (WHO) has developed a 12-point policy package…
HIV, Tuberculosis, and Viral Hepatitis: Drugs, diagnostics, Vaccines, and Microbicides in Development July 2009 By Lei Chou, Mark Harrington, Bob Huff, Richard Jefferys, Javid Syed, and Claire Wingfield TAG’s annual Pipeline Reportsurveys the developments in medicines and diagnostics most likely…
June 2009 By Lei Chou INTRODUCTION Welcome to this treatment guide for HIV-positive people who also have hepatitis B (HBV). This guide provides information on the prevention, care, and treatment of HBV, and the impact of HBV on HIV disease…
May 2009 by Lydia H. Guterman Edited by Mark Harrington Executive Summary The goal of this funding analysis is to provide a comprehensive picture of the current state of U.S. National Institutes of Health (NIH) research investment in HIV/AIDS and…